Taipei Bio Awards — Widely regarded as the “Biotech Oscars” of Taiwan’s Biotech Industry, the Taipei Biotech Award stands as the nation’s sole government-hosted accolade and the definitive benchmark of excellence in the biotechnology sector.
Marking its 22nd anniversary in 2025, the prestigious competition drew a highly competitive pool of 146 applications. The hallmark “Innovation Technology” category evaluated breakthroughs across four core pillars—Pharmaceuticals, Medical Devices, and Applied Biotechnology—awarding just a single Gold, Silver, and Bronze distinction in each field. Emerging at the forefront of the Applied Biotechnology cohort, Hughes Biotech clinched the coveted Gold Award, presented on stage by Taipei City Mayor Chiang Wan-An.
Hughes Biotech secured its top-tier finish by addressing one of the nutraceutical industry’s most persistent bottlenecks: oral bioavailability. The company’s pioneering platform integrates its world-first RenoSorb® postbiotic exosome technology with a pharmaceutical-grade, “inducible” absorption mechanism. This dual-action strategy successfully overcomes the oral absorption limitations inherent to various phytochemicals, maximizing clinically verified efficacy and establishing a new paradigm for precision nutrition.
Beyond serving as a robust validation of Hughes Biotech’s R&D capabilities and commercial viability, this landmark achievement underscores a broader industry trend—marking the steady ascent of Taiwanese biotechnology innovation onto the global stage.
